Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

149.30USD
23 May 2016
Change (% chg)

-- (--)
Prev Close
$149.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,630,384
52-wk High
$181.81
52-wk Low
$130.09

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $112,156.70
Shares Outstanding(Mil.): 751.22
Dividend: 1.00
Yield (%): 2.68

Financials

  AMGN.O Industry Sector
P/E (TTM): 15.80 40.28 35.51
EPS (TTM): 9.45 -- --
ROI: 11.17 -5.95 13.12
ROE: 26.15 -5.91 14.35

Fitch Rates Amgen Inc. Notes Offering 'BBB'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, May 13 (Fitch) Fitch Ratings has assigned a 'BBB' rating to Amgen Inc.'s (Amgen) notes offering. The company intends to use the net proceeds from this offering to repay select outstanding notes. The Rating Outlook is Stable. The ratings apply to $34.5 billion of debt outstanding at Mar. 31, 2016. A full list of Amgen's ratings can be found at the end of this release. KEY RATING DRIVERS --At 3.1x gross debt-to-EBITDA, Amgen'

May 13 2016

Sanofi presses on with threat to oust Medivation's board

France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a $9.3 billion acquisition offer.

May 13 2016

Sanofi presses on with threat to oust Medivation's board

May 13 France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a $9.3 billion acquisition offer.

May 13 2016

Regeneron CEO says drug price critique by independent group unscientific

NEW YORK Regeneron Pharmaceuticals Chief Executive Leonard Schleifer on Thursday took aim at an influential drug pricing watchdog, saying a critique of the company's new cholesterol lowering therapy was non-scientific.

May 12 2016

Regeneron CEO says drug price critique by independent group unscientific

NEW YORK, May 12 Regeneron Pharmaceuticals Chief Executive Leonard Schleifer on Thursday took aim at an influential drug pricing watchdog, saying a critique of the company's new cholesterol lowering therapy was non-scientific.

May 12 2016

Cigna makes deals with Amgen, Sanofi for pricey cholesterol drugs

NEW YORK, May 11 Cigna Corp signed deals that will pay the makers of Repatha and Praluent, two powerful but pricey cholesterol lowering treatments, based on how well their customers respond to the medicines, the health insurer said on Wednesday.

May 11 2016

Sanofi, Amgen cholesterol drugs win UK backing after price cuts

LONDON Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service.

May 05 2016

BRIEF-Xbiotech appoints Amgen veteran Scott Whitehurst as CFO

* Xbiotech appoints Amgen veteran Scott Whitehurst as chief financial officer

May 03 2016

Amgen profit sails past Street expectations; raises 2016 outlook

Amgen Inc on Thursday reported much higher-than-expected first-quarter profit as sales of several key drugs beat Wall Street estimates, and the company significantly raised its full-year earnings forecast.

Apr 28 2016

BRIEF-Amgen Q1 adjusted earnings per share $2.90

* Q1 earnings per share view $2.60 -- Thomson Reuters I/B/E/S

Apr 28 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.